Liver Fibrosis Market

Market Overview:

The 7 major liver fibrosis markets reached a value of US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5.1 Billion by 2034, exhibiting a growth rate (CAGR) of 7.39% during 2024-2034.

The liver fibrosis market has been comprehensively analyzed in IMARC's new report titled "Liver Fibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Liver fibrosis is a process of excessive scarring or fibrous tissue formation in the liver in response to injury or damage. Over time, the accumulation of scar cells can result in the liver becoming stiff and unable to function normally. Individuals suffering from this condition may initially experience decreased appetite, difficulty thinking clearly, accumulation of fluid in the legs or stomach, shortness of breath, nausea, unexplained weight loss, muscle weakness, etc. During later stages, the disease manifests as the appearance of yellowish color in the skin and eyes, confusion, abdominal swelling, reduced hormone production, bruising, dark urine, gastrointestinal bleeding, etc. The diagnosis of this ailment requires a combination of the patient's detailed medical history, underlying indications, and various blood tests. The healthcare provider may also perform several diagnostic procedures, like ultrasonography, computed tomography, magnetic resonance imaging, etc., to detect changes in the hepatic parenchyma associated with the moderate-to-severe disease condition. Liver biopsy and histologic examination are further recommended for the assessment of neuroinflammatory grades and stages of fibrosis in patients.

The increasing prevalence of injury and inflammation in the liver, which causes excessive buildup of proteins, such as collagen and glycoproteins, between the hepatic cells, is primarily driving the liver fibrosis market. In addition to this, the rising incidences of several associated risk factors, including excessive alcohol consumption, obesity, autoimmune hepatitis, destruction of the bile ducts, etc., are also bolstering the market growth. Furthermore, the escalating adoption of antifibrotic drugs, such as belapectin, cenicriviroc, liraglutide, etc., to help decrease the likelihood of permanent liver scarring in patients is acting as another significant growth-inducing factor. Additionally, the emerging popularity of next-generation plasma protein profiling, which aids in identifying potential biomarkers of liver fibrosis and understanding the disease mechanisms that can guide personalized treatment strategies, is also creating a positive outlook for the market. Moreover, the widespread demand for cell therapy for the treatment of this illness, since it can repair or replace damaged cells in the liver and enhance the production of hepatic enzymes, thereby improving the quality of life in patients, is expected to drive the liver fibrosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the liver fibrosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for liver fibrosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the liver fibrosis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the liver fibrosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the liver fibrosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current liver fibrosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the liver fibrosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the liver fibrosis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the liver fibrosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of liver fibrosis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of liver fibrosis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of liver fibrosis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with liver fibrosis across the seven major markets?
• What is the size of the liver fibrosis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of liver fibrosis?
• What will be the growth rate of patients across the seven major markets?
   

Liver Fibrosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for liver fibrosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the liver fibrosis market?
• What are the key regulatory events related to the liver fibrosis market?
• What is the structure of clinical trial landscape by status related to the liver fibrosis market?
• What is the structure of clinical trial landscape by phase related to the liver fibrosis market?
• What is the structure of clinical trial landscape by route of administration related to the liver fibrosis market?